Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection.
Treatment of Crohn's disease with infliximab is an important drug therapy for patients with refractory and fistulating disease. There are concerns over its use in a proportion of Crohn's patients with concurrent hepatitis C infection, since there are theoretical risks of accelerated hepatic decompensation due to the immunomodulatory impact of infliximab. We report a patient with both Crohn's disease and ongoing active hepatitis C infection who underwent infliximab therapy, with no worsening of his liver function or PCR status.
Gastrointestinal Unit, Western General Hospital, Edinburgh, UK. simoncampbell@hotmail.com
S
S
Campbell
S
S
Ghosh
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D000069285:Infliximab; D008297:Male
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab